HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
HOOKIPA Pharma Inc. (HOOK)
Last hookipa pharma inc. earnings: 3/19 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Food and Drug Administration (FDA) feedback HB-200 program received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) Received FDA clearance for Investigational New Drug (IND) application for HB-700 for the treatment of KRAS mutated cancers NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and recent business highlights for the first quarter of 2024. “The first quarter was about focus at HOOKIPA. We are embarking on a pivotal trial for HB-200 in combination with pembrolizumab and made important decisions to align our organization for late-stage clinical trial execution. We also added to the depth of our executive team with a new Chief Development Officer, Mark Winderlich, who brings crucial experience to help us execute on our clinical development strategy,” said Jo
Show less
Read more
Impact Snapshot
Event Time:
HOOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOOK alerts
High impacting HOOKIPA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
HOOK
News
- Hookipa Pharma Inc (NASDAQ: HOOK) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $5.00 price target on the stock.MarketBeat
- HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at HC Wainwright from $6.50 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab [Yahoo! Finance]Yahoo! Finance
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabGlobeNewswire
HOOK
Earnings
- 5/9/24 - Beat
HOOK
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/26/24 - Form ARS
- HOOK's page on the SEC website